Immunotherapeutic Strategies for the Treatment of Glioma

Immunotherapeutic Strategies for the Treatment of Glioma
Author: Christopher Jackson,Michael Lim
Publsiher: Academic Press
Total Pages: 190
Release: 2021-09-10
ISBN 10: 0128197560
ISBN 13: 9780128197561
Language: EN, FR, DE, ES & NL

Immunotherapeutic Strategies for the Treatment of Glioma Book Review:

Immunotherapeutic Strategies for the Treatment of Glioma provides a review of the current state of immunotherapy for primary brain tumors. The topic is of interest to patients, clinicians, and researchers alike, particularly given the recent failure of large clinical trials. This book serves as an overview of the most promising approaches in the field and provides a foundation for considering novel and combination therapies moving forward. The book discusses several types of immunotherapies for glioma, such as peptide, dendritic cell and heat shock protein vaccines; immune checkpoint blockade; myeloid cells as target; oncolytic viruses; and CAR T cell therapy. Additionally, it discusses the mechanisms of immune suppression in patients and immunogenomics. This volume is a valuable source for cancer researchers, oncologists and several members of biomedical field who are interested in novel strategies to fight glioblastoma. Summarizes the work in immunotherapy for glioma to-date, including the available evidence from preclinical studies and clinical trials Reviews the challenges and successes of the most promising strategies for brain tumor immunotherapy Provides a foundation for considering novel and combination therapies moving forward

Neurosurgical Procedures

Neurosurgical Procedures
Author: Alba Scerrati,Pasquale De Bonis
Publsiher: BoD – Books on Demand
Total Pages: 146
Release: 2020-04-22
ISBN 10: 1789859271
ISBN 13: 9781789859270
Language: EN, FR, DE, ES & NL

Neurosurgical Procedures Book Review:

In the last few years, the development of new technologies in the medical field has allowed procedures and improved surgical techniques to be performed, which until recently would have been unthinkable.Modern neurosurgery is forever tied to technological progress: the development of robotics and robotic-assisted surgery; enhanced visualization, perfusion, and function monitoring in vascular surgery; new techniques of bone reconstruction; new cerebral imaging tools; and alternative treatments such as laser interstitial thermal therapy or immunotherapy for tumors. This book is designed to be a comprehensive introduction to these new developments and to their application in clinical practice. We have tried to provide a unique background and insights to coherently present these new technologies.

Glioblastoma Resistance to Chemotherapy Molecular Mechanisms and Innovative Reversal Strategies

Glioblastoma Resistance to Chemotherapy  Molecular Mechanisms and Innovative Reversal Strategies
Author: Ramasamy Paulmurugan,Tarik F. Massoud
Publsiher: Academic Press
Total Pages: 828
Release: 2021-06-25
ISBN 10: 0128215682
ISBN 13: 9780128215685
Language: EN, FR, DE, ES & NL

Glioblastoma Resistance to Chemotherapy Molecular Mechanisms and Innovative Reversal Strategies Book Review:

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists, neuro-oncologists and other members of the biomedical field. Glioblastoma (GBM) is the most invasive and malignant primary brain tumor in humans with poor survival after diagnosis, therefore it is imperative that molecular and cellular mechanisms behind therapy resistant GBM cells, as well as the therapeutic strategies available to counter the resistance are comprehensively understood. Provides comprehensive, core knowledge related to the entire discipline of glioblastoma chemoresistance, from its many etiological mechanisms, to specific strategies to reverse resistance Presents current information from an international team of experts on the basic science, pre-clinical research, and clinical management of glioblastoma chemoresistance Discusses molecular and cellular mechanisms behind therapy resistant glioblastoma cells, as well as the therapeutic strategies available to counter this resistance

Regulation of Cancer Immune Checkpoints

Regulation of Cancer Immune Checkpoints
Author: Jie Xu
Publsiher: Springer Nature
Total Pages: 653
Release: 2020-03-17
ISBN 10: 9811532664
ISBN 13: 9789811532665
Language: EN, FR, DE, ES & NL

Regulation of Cancer Immune Checkpoints Book Review:

This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy. To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies.

The History of Oncology

The History of Oncology
Author: D. J. Th. Wagener
Publsiher: Bohn Stafleu van Loghum
Total Pages: 302
Release: 2009-07-13
ISBN 10: 9789031361434
ISBN 13: 9031361437
Language: EN, FR, DE, ES & NL

The History of Oncology Book Review:

‘The story of oncology is not only fascinating but also contains many accounts of dead ends, chance discoveries, illusions, mistakes and disappointments alongside the few successes.’These words are taken from the introduction to this book. The author, professor emeritus of Medical Oncology, reviews all aspects of the problem of cancer from a historical perspective, from the oldest existing records to the latest scientific and medical advances. It will interest the many people engaged in the treatment of cancer to read how the current therapeutic methods came about, and the book may also provide inspiration for cancer researchers, and for all those directly or indirectly involved with cancer. The layman looking for background information on a particular treatment may find it useful too. The various chapters can be read independently. A glossary and a few explanatory diagrams augment the text.This book grew out of an invitation the author received to lecture on the history of oncology. During his background reading, he discovered that there was no single volume dealing with the entire history of the subject. Fortunately, however, a great deal of information could be found here and there in the literature. As he read, he was struck by the fascinating stories behind many discoveries, and felt impelled to put them together in a single comprehensive account. The results of his labors are presented in this remarkable volume.The author, Prof. D.J.Th. (Theo) Wagener, was head of the department of Medical Oncology at the Radboud University Nijmegen Medical Centre in the Netherlands from 1982 to 2001, chairman of the Educational Committee of the European Society of Medical Oncology (ESMO), a member of the Educational Committee of the American Society of Clinical Oncology (ASCO) and a member of various international scientific working groups, mainly of the European Organization for Research and Treatment of Cancer (EORTC).

Brain Tumors

Brain Tumors
Author: Amit Agrawal,Luis Rafael Moscote-Salazar
Publsiher: BoD – Books on Demand
Total Pages: 248
Release: 2018-08-22
ISBN 10: 1789235561
ISBN 13: 9781789235562
Language: EN, FR, DE, ES & NL

Brain Tumors Book Review:

We all know that the field of neuro-oncology is heterogeneous and under continuous development with the addition of new knowledge and information on a regular basis. The present book "Brain Tumor - An Update" is an attempt to share the personal experiences of experts who are involved in neuro-oncology-related research. Through this book, the authors share their experiences and provide details about the pathophysiology, neuroimaging approaches, and management options, and how to go about decision-making in patients with brain tumors. We hope that the valuable contributions from the authors shall facilitate understanding about brain tumors. I am grateful to all the authors who have contributed their tremendous expertise, and I would like to acknowledge the outstanding support of Ms. Danijela Sakic, Author Service Manager, IntechOpen Science, who collaborated tirelessly in crafting this book.

Re Irradiation New Frontiers

Re Irradiation  New Frontiers
Author: Carsten Nieder,Johannes Langendijk
Publsiher: Springer
Total Pages: 364
Release: 2016-10-25
ISBN 10: 3319418254
ISBN 13: 9783319418254
Language: EN, FR, DE, ES & NL

Re Irradiation New Frontiers Book Review:

This book, now in its second edition, provides a comprehensive overview of current re-irradiation strategies, with detailed discussion of re-irradiation methods, technical aspects, the role of combined therapy with anticancer drugs and hyperthermia, and normal tissue tolerance. In addition, disease specific chapters document recent clinical results and future research directions. All chapters from the first edition have been revised and updated to take account of the latest developments and research findings, including those from prospective studies. Due attention is paid to the exciting developments in the fields of proton irradiation and frameless image-guided ablative radiotherapy. The book documents fully how refined combined modality approaches and significant technical advances in radiation treatment planning and delivery have facilitated the re-irradiation of previously exposed volumes, allowing both palliative and curative approaches to be pursued at various disease sites. Professionals involved in radiation treatment planning and multimodal oncology treatment will find it to be an invaluable aid in understanding the benefits and limitations of re-irradiation and in designing prospective trials.

Brain Tumor Immunotherapy

Brain Tumor Immunotherapy
Author: Linda M. Liau,Donald P. Becker,Timothy F. Cloughesy,Darell D. Bigner
Publsiher: Springer Science & Business Media
Total Pages: 374
Release: 2000-11-10
ISBN 10: 1592590357
ISBN 13: 9781592590353
Language: EN, FR, DE, ES & NL

Brain Tumor Immunotherapy Book Review:

An authoritative panel of researchers and clinicians critically reviews the entire field to provide a comprehensive guide to modern brain tumor immunotherapy and thereby enhance future research in this area. The contributors detail many of the key laboratory experiments and clinical protocols that are currently being investigated, integrate the available information from previous and ongoing research, and help define the current status of the field. Topics range from adoptive cellular and antibody-mediated immunotherapy of brain tumors to tumor vaccines and related strategies, and include many vanguard experimental strategies and immunological techniques for studying brain tumor immunotherapy. Cutting-edge and comprehensive, Brain Tumor Immunotherapy brings together all the important recent advances in our understanding of central nervous system tumor immunology and illustrates in powerful detail the many new applications now harnessing the immune response for brain tumor therapeutics.

Systemic Drug Delivery Strategies

Systemic Drug Delivery Strategies
Author: Mansoor M. Amiji,Lara Scheherazade Milane
Publsiher: Elsevier
Total Pages: 588
Release: 2021-09-17
ISBN 10: 0323857817
ISBN 13: 9780323857819
Language: EN, FR, DE, ES & NL

Systemic Drug Delivery Strategies Book Review:

Systemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2 examines the challenges of delivering immuno-oncology therapies, focusing specifically on the multiple technologies of affective drug delivery strategies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. This volume of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy discusses methods of targeting tumors, CRISPR technology, and vaccine delivery among many other delivery strategies. Systemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2 creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. Comprehensive treaty covering all aspects of immuno-oncology (IO) Novel strategies for delivery of IO therapeutics and vaccines Forecasting on the future of nanotechnology and drug delivery for IO

Glioma

Glioma
Author: ryuya yamanaka
Publsiher: Springer Science & Business Media
Total Pages: 232
Release: 2012-05-27
ISBN 10: 1461431468
ISBN 13: 9781461431466
Language: EN, FR, DE, ES & NL

Glioma Book Review:

Treatment of glioma is currently one of the most challenging problems in oncology, as well as in neurosurgery. Despite major advances in our understanding of the pathomechanism, diagnosis by imaging and the availability of powerful therapeutic tools, the life expectancy of patients with glioblastoma has only been slightly prolonged and a cure remains elusive. None of the currently available surgical tools, including operative microscopes, lasers and image-guided surgery, can enable the detection and removal of all of the tumor tissue. In recent years, however, the landscape has been changing immeasurably, and molecular studies over the past two decades have identified a variety of genetic aberrations that are specifically associated with individual types of gliomas. In addition, certain molecular abnormalities have been linked to therapy responses, thereby establishing clinical biomarkers and molecular targets, and the use of novel agents is being investigated. These agents have been specifically engineered to exert specific cytotoxicity against gliomas, either on their own as single agents or in combination with other modalities. Moreover, there has been an enormous surge of interest in the area of immunology and immunotherapy, which has been facilitated by our understanding of the molecular basis of gliomas. Although several kinds of immunotherapeutic trials have been undertaken, we still await a great breakthrough in terms of clinical efficacy to prolong the survival time of glioma patients.

Enhancing Immunity to Glioma Modulating the Adaptive Immune Response in the Tumor Microenvironment

Enhancing Immunity to Glioma  Modulating the Adaptive Immune Response in the Tumor Microenvironment
Author: Joseph Paul Antonios
Publsiher: Unknown
Total Pages: 141
Release: 2016
ISBN 10: 1928374650XXX
ISBN 13: OCLC:1078248219
Language: EN, FR, DE, ES & NL

Enhancing Immunity to Glioma Modulating the Adaptive Immune Response in the Tumor Microenvironment Book Review:

Glioblastoma (GBM) is the most common and lethal of all adult primary malignant brain tumors. For patients diagnosed with GBM, the median survival is 11-14 months despite advances in surgical resection techniques, chemotherapies, and radiation therapy (1). Alternate therapeutic strategies are being actively pursued to target GBM, with various immunotherapeutic modalities designed to generate an anti-GBM immune response showing considerable promise in preclinical models and clinical trials. To more effectively target GBM with these treatments, there has been an increasing appreciation of the numerous mechanisms involved in generating and maintaining the highly immunosuppressive tumor microenvironment in recent years. These studies have described a variety of microenvironmental and systemic factors that promote glioma cell evasion from the immune system. In light of these, it has become apparent that these factors must be understood and explicitly targeted to mount a successful immune response against GBM. This thesis describes the utilization of two different immunotherapeutic strategies to target GBM. The first strategy created a novel GBM target by inducing NY-ESO-1 antigen expression with the demethylating agent, decitabine, and targeting that antigen with engineered T cells. Specifically, we utilized human GBM cell cultures to induce expression of the antigen. We evaluated NY-ESO-1 TCR-transduced T cell-mediated GBM tumor cytolysis in a series of in vitro cytotoxicity assays. Following this, we examined the application of this therapy using an intracranially-implanted xenograft model. Our studies demonstrated that decitabine could effectively upregulate NY-ESO-1 both in vivo and in vitro. Engineered T cells were able to induce tumor cytolysis in vitro and were able to traffic to and target tumor in vivo. Tumor-bearing mice receiving adoptive transfer of these engineered T cells demonstrated significantly increased survival over mice that received non-transduced T cells. By inducing expression of a novel target on GBM, we were able to generate a highly specific, anti-GBM immune response. This strategy represented a clinically translatable therapeutic technique for treating patients with GBM. The second strategy focused on using existing GBM targets to generate an endogenous immune response in a syngeneic, immune competent mouse model. Briefly, we administered an autologous tumor lysate-pulsed dendritic cell (DC) vaccine to produce a glioma-specific immune response. In our studies, the vaccination appeared to be capable of inducing T cell infiltration into tumors; however, in large, established tumors, this infiltrating response was not sufficient to increase mouse survival and provide significant therapeutic benefit. We described the role of the negative costimulatory pathway, programmed death-1/ligand-1 (PD-1/PD-L1) in mitigating T cell activation and memory in a series of in vitro and in vivo studies. We noted that PD-1 blockade with PD-1 mAb was not sufficient to produce a T cell infiltrate. However, when administered with DC vaccination, PD-1 blockade activated the vaccine-generated T cell response in the tumor microenvironment. We found that T cells with PD-1 mAb were able to mediate significant tumor cytolysis when compared to T cells without PD-1 blockade in vitro. The adjuvant administration of PD-1 mAb with the DC vaccine resulted in significant survival benefit over DC vaccine alone in mice bearing large, established gliomas. Additionally, this dual treatment resulted in the increased expression of integrin homing and immunologic memory markers on T cells infiltrating tumor. These findings were corroborated in samples from patient GBM, with PD-1 blockade enhancing the T cell-mediated GBM cytolysis. Concerning this strategy, then, these findings provided us with a means to both generate and enhance a tumor-specific response. While this second strategy proved effective, the mechanism underlying this PD-1/PD-L1-mediated suppression was not fully understood. As such, we proceeded to identify a PD-L1-expressing tumor infiltrating myeloid (TIM) cell population that appeared to dominantly regulate the PD-1/PD-L1 signaling mechanism. Importantly, we determined the role that these cells play in inhibiting the immune response using a series of in vitro and in vivo studies utilizing TIM depletion and PD-1 mAb treatment strategies. We found that depletion of TIMs in both human GBM cultures and murine glioma abolished PD-1/PD-L1-mediated inhibition of T cell activation. Targeting TIMs with colony stimulating factor-1 receptor inhibitor (CSF-1Ri) reduced the TIM population significantly and altered the remaining TIMs such that they demonstrated increased expression of chemotactic factors. While treatment with CSF-1Ri in conjunction with DC vaccine did not alter PD-L1 expression on remaining TIMs, we did note that there was increased TIL infiltration with this dual treatment significantly over DC vaccine alone. These findings suggested that TIMs exert inhibitory effects in the tumor microenvironment in a manner not restricted only to the PD-1/PD-L1 signaling mechanism. We found that the combined treatment of CSF-1Ri and PD-1 mAb with DC vaccination both increased TIL infiltration and activation in the tumor microenvironment. These findings were therapeutically relevant, with tumor-bearing mice receiving all three treatments showing a significant increase in survival over mice receiving each treatment alone. The studies outlined herein elucidated the role that TIMs play in dominantly mediating the PD-1/PD-L1 signaling mechanism to restrict TIL activation, as well as the ability to manipulate this population pharmacologically with clinically accessible agents. In conclusion, this thesis demonstrates two distinct strategies to generate and enhance an immune response against GBM. In our first strategy, we utilized the adoptive transfer of engineered T cells to selectively target an antigen whose expression we artificially induced in GBM. This technique was largely effective. However, we were interested in directly targeting antigens already expressed by GBM. To that end, we described the utility of DC vaccination in generating an immune response. Further, we delineated the inhibitory mechanisms employed by TIMs in the tumor microenvironment and developed a therapeutic adjuvant to administer with DC vaccination. We confirmed the efficacy of these treatments in a series of in vitro and in vivo animal studies, and we recapitulated these findings in our novel, ex vivo human GBM studies. Together, the studies presented in this thesis represent an innovative approach to understanding and immunotherapeutically targeting the GBM microenvironment.

Pediatric Neuro oncology

Pediatric Neuro oncology
Author: Katrin Scheinemann,Eric Bouffet
Publsiher: Springer
Total Pages: 318
Release: 2015-03-26
ISBN 10: 149391541X
ISBN 13: 9781493915415
Language: EN, FR, DE, ES & NL

Pediatric Neuro oncology Book Review:

“The editors...have done an outstanding job of presenting...complex information in a lucid manner – this book is a must-read for the global community of aspiring students and neuro-oncology practitioners.” Amar Gajjar, MD in the Foreword This is a succinct introduction to pediatric neuro-oncology. It summarizes the key advances in molecular biology that have helped transform this rapidly evolving field and provides up-to-date coverage of major and emerging treatment modalities as well as supportive care. Separate chapters present each kind of pediatric brain cancer and its diagnosis and treatment. As more children survive brain cancer, the importance of quality of life issues and helping survivors to cope with the neuropsychological impact and long-term effects of current therapies has come into sharper focus; these topics are also addressed in the book, as are palliative care and pediatric neuro-oncology in countries with limited resources. The book is aimed at trainees and practitioners who seek an up-to-date text in pediatric neuro-oncology that is both comprehensive and concise.

Stem Cells From Hype to Real Hope

Stem Cells     From Hype to Real Hope
Author: Khawaja Husnain Haider,Salim Aziz, MD
Publsiher: Walter de Gruyter GmbH & Co KG
Total Pages: 220
Release: 2018-12-17
ISBN 10: 3110587041
ISBN 13: 9783110587043
Language: EN, FR, DE, ES & NL

Stem Cells From Hype to Real Hope Book Review:

This book is a compilation of the bench experience of leading experts from various research labs involved in the cutting edge area of research. The authors describe the use of stem cells both as part of the combinatorial therapeutic intervention approach and as tools (disease model) during drug development, highlighting the shift from a conventional symptomatic treatment strategy to addressing the root cause of the disease process. The book is a continuum of the previously published book entitled "Stem Cells: from Drug to Drug Discovery" which was published in 2017.

Textbook of Clinical Trials in Oncology

Textbook of Clinical Trials in Oncology
Author: Susan Halabi,Stefan Michiels
Publsiher: CRC Press
Total Pages: 626
Release: 2019-04-24
ISBN 10: 1351620975
ISBN 13: 9781351620970
Language: EN, FR, DE, ES & NL

Textbook of Clinical Trials in Oncology Book Review:

There is an increasing need for educational resources for statisticians and investigators. Reflecting this, the goal of this book is to provide readers with a sound foundation in the statistical design, conduct, and analysis of clinical trials. Furthermore, it is intended as a guide for statisticians and investigators with minimal clinical trial experience who are interested in pursuing a career in this area. The advancement in genetic and molecular technologies have revolutionized drug development. In recent years, clinical trials have become increasingly sophisticated as they incorporate genomic studies, and efficient designs (such as basket and umbrella trials) have permeated the field. This book offers the requisite background and expert guidance for the innovative statistical design and analysis of clinical trials in oncology. Key Features: Cutting-edge topics with appropriate technical background Built around case studies which give the work a "hands-on" approach Real examples of flaws in previously reported clinical trials and how to avoid them Access to statistical code on the book’s website Chapters written by internationally recognized statisticians from academia and pharmaceutical companies Carefully edited to ensure consistency in style, level, and approach Topics covered include innovating phase I and II designs, trials in immune-oncology and rare diseases, among many others

Intracranial Gliomas Part III Innovative Treatment Modalities

Intracranial Gliomas Part III   Innovative Treatment Modalities
Author: M.F. Chernov,Y. Muragaki,S. Kesari,I.E. McCutcheon
Publsiher: Karger Medical and Scientific Publishers
Total Pages: 222
Release: 2018-07-10
ISBN 10: 3318060631
ISBN 13: 9783318060638
Language: EN, FR, DE, ES & NL

Intracranial Gliomas Part III Innovative Treatment Modalities Book Review:

At present most intracranial gliomas are considered incurable with current treatment strategies, and the search for new modalities that may effectively control tumor growth continues. The chapters in this volume describe basic principles and therapeutic possibilities of several innovative techniques, including photodynamic therapy, laser-induced interstitial thermotherapy, stereotactic cryodestruction, high-intensity focused ultrasound ablation, boron neutron capture therapy, proton and carbon ion irradiation, targeted therapy, immunotherapy, gene therapy, local chemotherapy, and alternating electric fields therapy. Potential applications of extracellular vesicles and nanotechnology for management of gliomas are highlighted as well. Many of these methods have already demonstrated antitumor efficacy in clinical testing, whereas others are still under development. The materials presented in this book are mainly directed at clinicians treating patients with brain tumors, as well as clinical and basic researchers working in the field of neuro-oncology.

Brain and Spinal Tumors

Brain and Spinal Tumors
Author: Lee Roy Morgan,Feyzi Birol Sarica
Publsiher: BoD – Books on Demand
Total Pages: 276
Release: 2020-01-29
ISBN 10: 1789841577
ISBN 13: 9781789841572
Language: EN, FR, DE, ES & NL

Brain and Spinal Tumors Book Review:

Numerous new concepts and procedures are reviewed and discussed in this book and allude to the transport of drugs to the brain. New radiation concepts are also presented, plus management of toxicities associated with both treatment modalities. It is the goal of this book to provide information and data that will be useful for both researchers and practitioners to develop new approaches for the management of CNS malignancies.

Keto for Cancer

Keto for Cancer
Author: Miriam Kalamian
Publsiher: Chelsea Green Publishing
Total Pages: 400
Release: 2017
ISBN 10: 1603587012
ISBN 13: 9781603587013
Language: EN, FR, DE, ES & NL

Keto for Cancer Book Review:

A Comprehensive Guide for Patients and Practitioners Although evidence supporting the benefits of ketogenic diet therapies continues to mount, there is little to guide those who wish to adopt this diet as a metabolic therapy for cancer. Keto for Cancer fills this need. Inspired by the work of Dr. Thomas N. Seyfried, PhD, nutritionist Miriam Kalamian has written the first book to lay out comprehensive guidelines that specifically address the many challenges associated with cancer, and particularly the deep nutritional overhaul involved with the ketogenic diet. Kalamian, a leading voice in the keto movement, is driven by passion from her own experience in using the ketogenic diet for her young son. Her book addresses the nuts and bolts of adopting the diet, from deciding whether keto is the right choice to developing a personal plan for smoothly navigating the keto lifestyle. It is invaluable for both beginners and seasoned users of the ketogenic diet, as well as for health-care professionals who need a toolkit to implement this targeted metabolic therapy. The book guides readers to a deeper understanding of the therapeutic potential of the ketogenic diet--which extends well beyond simply starving cancer--emphasizing the powerful impact the diet has on the metabolism of cancer cells. Nutritional nuances are explored in sections such as "Fasting Protocols" and "Know What's in the Foods You Eat" while meal templates and tracking tools are provided in "Preparing Keto Meals." Kalamian also discusses important issues such as self-advocacy. Readers of Keto for Cancer are empowered to "get off the bench and get in the game." To that end, Kalamian offers tips on how to critically examine cancer-care options then incorporate what resonates into a truly personalized treatment plan.

Cutaneous Melanoma

Cutaneous Melanoma
Author: Anonim
Publsiher: Unknown
Total Pages: 135
Release: 2022
ISBN 10: 1928374650XXX
ISBN 13: OCLC:1125727614
Language: EN, FR, DE, ES & NL

Cutaneous Melanoma Book Review:

Engineering Technologies and Clinical Translation

Engineering Technologies and Clinical Translation
Author: Mansoor M. Amiji,Lara Scheherazade Milane
Publsiher: Academic Press
Total Pages: 524
Release: 2021-08-25
ISBN 10: 0323909507
ISBN 13: 9780323909501
Language: EN, FR, DE, ES & NL

Engineering Technologies and Clinical Translation Book Review:

Engineering Technologies and Clinical Translation: Volume 3: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies, focusing specifically on the development of solutions for drug delivery and its clinical outcomes. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. This volume of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy discusses biomaterial, microfluidic, and biodegradable devices, engineered microbes, personalized medicine, clinical approval process, and many other IO technologies. Engineering Technologies and Clinical Translation: Volume 3: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. Explores engineering technologies and their clinical translation in a comprehensive way Presents forecasting on the future of nanotechnology and drug delivery for IO Engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side

Modern Management of High Grade Glioma Part II An Issue of Neurosurgery Clinics E Book

Modern Management of High Grade Glioma  Part II  An Issue of Neurosurgery Clinics   E Book
Author: Isaac Yang,Seunggu J. Han
Publsiher: Elsevier Health Sciences
Total Pages: 240
Release: 2012-07-15
ISBN 10: 1455747688
ISBN 13: 9781455747689
Language: EN, FR, DE, ES & NL

Modern Management of High Grade Glioma Part II An Issue of Neurosurgery Clinics E Book Book Review:

Standard therapy for high grade glioma is a topic that is evolving, timely, and relevant. Guest Editors Isaac Yang, MD and Seunggu Han, MD have assembled a group of experts on management of high grade glioma. Some of the articles in this issue include: Use of language mapping to aid resection of eloquent gliomas; Clinical trials with immunotherapy; Clinical trials for small molecule inhibitors; Nanotechnology potential applications for GBM therapy; High Grade Gliomas in children; Modern Advances in Brain Tumor Treatments; Molecular pathways of Avastin interactions for the treatment of glioblastoma; and Quality of Life and Outcomes in Glioblastoma management.